<div class="csl-bib-body">
<div class="csl-entry">Polechová, J., Johnson, K. D., Payne, P., Crozier, A., Beiglböck, M., Plevka, P., & Schernhammer, E. (2022). SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools. <i>Journal of Clinical Epidemiology</i>, <i>145</i>, 14–19. https://doi.org/10.1016/j.jclinepi.2022.01.002</div>
</div>
-
dc.identifier.issn
0895-4356
-
dc.identifier.uri
http://hdl.handle.net/20.500.12708/168409
-
dc.description.abstract
Objective
This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test.
Study Design and Setting
We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.
Results
Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort.
Conclusion
Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic.
en
dc.language.iso
en
-
dc.publisher
ELSEVIER SCIENCE INC
-
dc.relation.ispartof
Journal of Clinical Epidemiology
-
dc.subject
Austria
en
dc.subject
Child
en
dc.subject
Humans
en
dc.subject
Pandemics
en
dc.subject
Schools
en
dc.subject
Sensitivity and Specificity
en
dc.subject
COVID-19
en
dc.subject
Large-scale testing
en
dc.subject
Lateral flow device
en
dc.subject
Public health
en
dc.subject
Repeat testing
en
dc.subject
SARS-CoV-2
en
dc.subject
COVID-19
en
dc.subject
SARS-CoV-2
en
dc.title
SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools